Gildess Fe 1 / 20 is a birth control medication containing progestin and estrogen. The main components are ethinyl estradiol, norethindrone and ferrum ferrate. This drug is prescribed for providing a protection from unwanted pregnancies.
Indications for use
- Hormonal contraception;
- Stimulation or delay of menstruation processes;
- Infertility treatment due to functional disorders;
- Uterine hypoplasia;
- Functional disorders of the menstrual cycle;
Mechanism of action
Norethisterone acetate and ethinyl estradiol are active synthetic gestagen and estrogen (respectively). Gildess Fe 1 / 20 is a birth control preparation for oral administration with a predominant progestogen content.
This drug action is defined by inhibition of the gonadotropic function of the pituitary gland: suppressing FSH production, the drug prevents the egg maturation in the follicle and ovulation, as well as cyclic changes in the endometrium, preventing its implantation capability.
Due to the combination of estrogen with gestagen, the drug can stimulate and delay menstruation and help stop acyclic uterine bleeding in the case of the appropriate application regimens.
Mode of application and dosage
Gildess Fe 1 / 20 is prescribed for an oral administration. The dosage of this birth control drug is 1 mg/20 mcg. The course lasts for 28 days. 1 pill should be taken daily at one and the same time washed down with a glass of water. 21 pills of Gildess Fe 1 / 20 contain active hormones when the latest 7 contain Ferrum ferrate. During their application, the menstruation starts. When the first 28 pills are taken start a new package without any breaks.
Hypersensitivity to Gildess Fe 1/20 is a direct contraindication. In addition, this preparation is prohibited if you have the following health conditions:
- active hepatic disorders;
- postoperative thromboembolism;
- history of jaundice during a previous pregnancy;
- coronary and cerebrovascular disease inclusively of the medical history;
- oncoming basic operations;
- suspicion of malignant genitalia/breast tumors;
- Tenderness of the mammary glands;
- The appearance of brown spots on the skin;
- The intolerance of wearing contact lenses.
The effectiveness of Gildess Fe 1 / 20 may decrease with the simultaneous use of narcotic drugs, analgesics, tranquilizers, anticonvulsants, certain antibiotics and other drugs that affect the activity of microsomal oxidase enzymes. When taking this birth control drug, the effectiveness of insulin or oral hypoglycemic drugs may be decreased.
What if I miss a dose?
If you miss a pill, take it as soon as possible. If the time of the next appointment is coming, you can skip the previous pill and continue to follow your common regimen of taking medications. Do not take an additional the drug’s dose to compensate for a missed appointment. If such a situation takes place constantly, think about the possibility of setting a reminder note or ask one of your family members to follow the schedule.
Gildess Fe 1/20 and pregnancy
If the pregnancy is diagnosed during Gildess Fe 1 / 20 intake, the drug should be immediately discontinued.
There were carried out extensive epidemiological studies which did not clear out a magnified risk of developmental defects in children born to women who received sex hormones before pregnancy or teratogenicity, in cases where sex hormones were mistaken for early pregnancy.
In animal studies, the effects of norethindrone and ethinyl estradiol were related to their pharmacological action. In particular, in studies of reproductive toxicity, embryotoxic and fetotoxic effects were detected in animals, but these effects were considered to be related to the specificity of a particular animal species. At exposure levels in animals exceeding the corresponding levels in women taking norethindrone and ethinyl estradiol, the sex differentiation of rat embryos was observed, which was absent in small monkeys.
According to the data obtained in animal studies, it is impossible to exclude the possibility of developing undesirable effects caused by the hormonal activity of the active substances in humans. However, the combined experience of the COCs use during pregnancy did not provide evidence of the development of unwanted effects in humans. Data on the results during pregnancy are limited, which does not allow to draw any conclusions about the negative effect of the drug on pregnancy, fetal and newborn health. Currently, there are no significant epidemiological data.
Breastfeeding period. The drug is contraindicated during the period of breastfeeding. It can reduce the amount of breast milk and change its composition, so the use of the drug is not recommended until the end of breastfeeding. A small number of sex hormones and/or their metabolites can penetrate the breast milk, but there is no evidence of their negative impact on the newborn health.